SCHEMBL3704253

SCHEMBL3704253

Fc1cc(Nc2nc(N3CCC(CNCC(F)F)CC3)c3occc3n2)ccc1N1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.47
SYK P43405 3/20 0.47
ABL1 P00519 1/20 0.47
INSR P06213 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
RET P07949 1/20 0.47
MST1 P26927 1/20 0.47
TTK P33981 1/20 0.47
MAPK8 P45983 1/20 0.47
TNK2 Q07912 1/20 0.47
MAP4K2 Q12851 1/20 0.47
NTRK2 Q16620 1/20 0.47
LMNA P02545 4/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 3/20 0.42
MAPK1 P28482 2/20 0.42
TSHR P16473 1/20 0.42
JAK3 P52333 5/20 0.40
BTK Q06187 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707381 0.92 JAK2 (0.57) JAK2SYKABL1INSRLCK
SCHEMBL1709935 0.80 SYK (0.51) JAK2SYKABL1LCKFYN
SCHEMBL3712042 0.80 SYK (0.40) JAK2SYKABL1INSRLCK
SCHEMBL3700643 0.79 SYK (0.37) JAK2SYKABL1INSRLCK
SCHEMBL1709934 0.78 JAK2 (0.60) JAK2SYKABL1INSRLCK
SCHEMBL3711317 0.78 JAK2 (0.56) JAK2SYKABL1INSRLCK
SCHEMBL1709768 0.78 SYK (0.44) JAK2SYKABL1INSRLCK
SCHEMBL3711654 0.78 SYK (0.55) JAK2SYKABL1INSRLCK
SCHEMBL3703870 0.78 SYK (0.36) JAK2SYKABL1INSRLCK
SCHEMBL3711623 0.77 SYK (0.46) JAK2SYKABL1INSRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US claimed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 JAK2 218/4885SYK 1176/4885ABL1 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.